RU2009127709A - Новые способы функционального анализа большого количества экспериментальных данных и групп генов, идентифицированных из указанных данных - Google Patents
Новые способы функционального анализа большого количества экспериментальных данных и групп генов, идентифицированных из указанных данных Download PDFInfo
- Publication number
- RU2009127709A RU2009127709A RU2009127709/10A RU2009127709A RU2009127709A RU 2009127709 A RU2009127709 A RU 2009127709A RU 2009127709/10 A RU2009127709/10 A RU 2009127709/10A RU 2009127709 A RU2009127709 A RU 2009127709A RU 2009127709 A RU2009127709 A RU 2009127709A
- Authority
- RU
- Russia
- Prior art keywords
- breast cancer
- tissue sample
- descriptor
- classifying
- positive
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract 7
- 238000010230 functional analysis Methods 0.000 title 1
- 239000000523 sample Substances 0.000 claims abstract 19
- 206010006187 Breast cancer Diseases 0.000 claims abstract 17
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract 17
- 238000000034 method Methods 0.000 claims abstract 12
- 230000000295 complement effect Effects 0.000 claims abstract 8
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims abstract 6
- 230000014509 gene expression Effects 0.000 claims abstract 6
- 239000002751 oligonucleotide probe Substances 0.000 claims abstract 6
- 238000003757 reverse transcription PCR Methods 0.000 claims abstract 6
- 230000002018 overexpression Effects 0.000 claims abstract 5
- 102100030346 Antigen peptide transporter 1 Human genes 0.000 claims abstract 4
- 102100031502 Collagen alpha-2(V) chain Human genes 0.000 claims abstract 4
- 102100034560 Cytosol aminopeptidase Human genes 0.000 claims abstract 4
- 102100038595 Estrogen receptor Human genes 0.000 claims abstract 4
- 102000017700 GABRP Human genes 0.000 claims abstract 4
- 108700031843 GRB7 Adaptor Proteins 0.000 claims abstract 4
- 101150052409 GRB7 gene Proteins 0.000 claims abstract 4
- 101710088083 Glomulin Proteins 0.000 claims abstract 4
- 102100033107 Growth factor receptor-bound protein 7 Human genes 0.000 claims abstract 4
- 101000941594 Homo sapiens Collagen alpha-2(V) chain Proteins 0.000 claims abstract 4
- 101000924389 Homo sapiens Cytosol aminopeptidase Proteins 0.000 claims abstract 4
- 101000882584 Homo sapiens Estrogen receptor Proteins 0.000 claims abstract 4
- 101000822394 Homo sapiens Gamma-aminobutyric acid receptor subunit pi Proteins 0.000 claims abstract 4
- 101000998027 Homo sapiens Keratin, type I cytoskeletal 17 Proteins 0.000 claims abstract 4
- 101000998020 Homo sapiens Keratin, type I cytoskeletal 18 Proteins 0.000 claims abstract 4
- 101001056473 Homo sapiens Keratin, type II cytoskeletal 5 Proteins 0.000 claims abstract 4
- 101000975496 Homo sapiens Keratin, type II cytoskeletal 8 Proteins 0.000 claims abstract 4
- 101000962131 Homo sapiens Mediator of RNA polymerase II transcription subunit 1 Proteins 0.000 claims abstract 4
- 101001019109 Homo sapiens Mediator of RNA polymerase II transcription subunit 24 Proteins 0.000 claims abstract 4
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims abstract 4
- 101001068027 Homo sapiens Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform Proteins 0.000 claims abstract 4
- 101000929936 Homo sapiens Short/branched chain specific acyl-CoA dehydrogenase, mitochondrial Proteins 0.000 claims abstract 4
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 claims abstract 4
- 101000819111 Homo sapiens Trans-acting T-cell-specific transcription factor GATA-3 Proteins 0.000 claims abstract 4
- 101000634975 Homo sapiens Tripartite motif-containing protein 29 Proteins 0.000 claims abstract 4
- 101000761740 Homo sapiens Ubiquitin/ISG15-conjugating enzyme E2 L6 Proteins 0.000 claims abstract 4
- 101000638886 Homo sapiens Urokinase-type plasminogen activator Proteins 0.000 claims abstract 4
- 101000666295 Homo sapiens X-box-binding protein 1 Proteins 0.000 claims abstract 4
- 102100033511 Keratin, type I cytoskeletal 17 Human genes 0.000 claims abstract 4
- 102100033421 Keratin, type I cytoskeletal 18 Human genes 0.000 claims abstract 4
- 102100025756 Keratin, type II cytoskeletal 5 Human genes 0.000 claims abstract 4
- 102100023972 Keratin, type II cytoskeletal 8 Human genes 0.000 claims abstract 4
- 102100039204 Mediator of RNA polymerase II transcription subunit 1 Human genes 0.000 claims abstract 4
- 102100034821 Mediator of RNA polymerase II transcription subunit 24 Human genes 0.000 claims abstract 4
- 108010023335 Member 2 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims abstract 4
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 claims abstract 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims abstract 4
- 108010044012 STAT1 Transcription Factor Proteins 0.000 claims abstract 4
- 102100034464 Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform Human genes 0.000 claims abstract 4
- 102100035766 Short/branched chain specific acyl-CoA dehydrogenase, mitochondrial Human genes 0.000 claims abstract 4
- 102100029904 Signal transducer and activator of transcription 1-alpha/beta Human genes 0.000 claims abstract 4
- 102100026719 StAR-related lipid transfer protein 3 Human genes 0.000 claims abstract 4
- 101150020213 Stard3 gene Proteins 0.000 claims abstract 4
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 claims abstract 4
- 102100021386 Trans-acting T-cell-specific transcription factor GATA-3 Human genes 0.000 claims abstract 4
- 108010078184 Trefoil Factor-3 Proteins 0.000 claims abstract 4
- 102000014456 Trefoil Factor-3 Human genes 0.000 claims abstract 4
- 102100029519 Tripartite motif-containing protein 29 Human genes 0.000 claims abstract 4
- 102100024843 Ubiquitin/ISG15-conjugating enzyme E2 L6 Human genes 0.000 claims abstract 4
- 102100031358 Urokinase-type plasminogen activator Human genes 0.000 claims abstract 4
- 102100038151 X-box-binding protein 1 Human genes 0.000 claims abstract 4
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract 3
- 239000011159 matrix material Substances 0.000 claims abstract 3
- 239000007787 solid Substances 0.000 claims abstract 3
- 239000003155 DNA primer Substances 0.000 claims abstract 2
- 230000004547 gene signature Effects 0.000 claims abstract 2
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 238000009396 hybridization Methods 0.000 claims 3
- 230000003321 amplification Effects 0.000 claims 2
- 238000003199 nucleic acid amplification method Methods 0.000 claims 2
- 238000004393 prognosis Methods 0.000 claims 2
- 238000005259 measurement Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
1. Изделие для классификации образца ткани рака молочной железы, которое включает средство для измерения экспрессии генов в следующих дескрипторных группах: ! (1) ERBB2, STARD3, GRB7, THRAP4, PPARBP; ! (2) ESR1, GATA3, XBP1, TFF3, ACADSB; ! (3) KRT5, KRT17, TRIM29, GABRP; ! (4) KRT18, KRT8, PPP2CA, KRT8L2; ! (5) PLAU, COL5A2, FAP, THY1; ! (6) STAT1, UBE2L6, TAP1, LAP3 и ! (7) SEACAM5, SEACAM6, SEACAM7, ! где сверхэкспрессия большинства генов в дескрипторной группе показывает, что образец ткани является положительным для данной группы, и отсутствие сверхэкспрессии большинства генов в дескрипторной группе показывает, что образец ткани является отрицательным для данной группы; и ! где комбинация положительных и/или отрицательных статусов дескрипторных групп образует генную сигнатуру для классификации образца ткани рака молочной железы. ! 2. Изделие по п.1, в котором средство для измерения экспрессии генов включает комплементарные олигонуклеотидные зонды или затравки. ! 3. Изделие по п.2, в котором комплементарные олигонуклеотидные зонды иммобилизованы на твердом носителе. ! 4. Изделие по п.3, в котором иммобилизованные комплементарные олигонуклеотидные зонды образуют олигонуклеотидную матрицу. ! 5. Изделие по п.2, в котором комплементарные олигонуклеотидные праймеры пригодны для выполнения полимеразной цепной реакции с обратной транскрипцией (RT-PCR). ! 6. Способ классификации образца ткани рака молочной железы, который включает: ! (а) измерение экспрессии генов в образце ткани в следующих дескрпиторных группах: ! (1) ERBB2, STARD3, GRB7, THRAP4, PPARBP; ! (2) ESR1, GATA3, XBP1, TFF3, ACADSB; ! (3) KRT5, KRT17, TRIM29, GABRP; ! (4) KRT18, KRT8, PPP2CA, KRT8L2; ! (5) PLAU, COL5A2, FAP, THY1; ! (6) STAT1, UBE2L6, TAP1, LAP3 и ! (7) SEACAM5, SEACAM6, SEACAM7; ! (b) присвоение положительного или отрицательного статуса каждой из
Claims (13)
1. Изделие для классификации образца ткани рака молочной железы, которое включает средство для измерения экспрессии генов в следующих дескрипторных группах:
(1) ERBB2, STARD3, GRB7, THRAP4, PPARBP;
(2) ESR1, GATA3, XBP1, TFF3, ACADSB;
(3) KRT5, KRT17, TRIM29, GABRP;
(4) KRT18, KRT8, PPP2CA, KRT8L2;
(5) PLAU, COL5A2, FAP, THY1;
(6) STAT1, UBE2L6, TAP1, LAP3 и
(7) SEACAM5, SEACAM6, SEACAM7,
где сверхэкспрессия большинства генов в дескрипторной группе показывает, что образец ткани является положительным для данной группы, и отсутствие сверхэкспрессии большинства генов в дескрипторной группе показывает, что образец ткани является отрицательным для данной группы; и
где комбинация положительных и/или отрицательных статусов дескрипторных групп образует генную сигнатуру для классификации образца ткани рака молочной железы.
2. Изделие по п.1, в котором средство для измерения экспрессии генов включает комплементарные олигонуклеотидные зонды или затравки.
3. Изделие по п.2, в котором комплементарные олигонуклеотидные зонды иммобилизованы на твердом носителе.
4. Изделие по п.3, в котором иммобилизованные комплементарные олигонуклеотидные зонды образуют олигонуклеотидную матрицу.
5. Изделие по п.2, в котором комплементарные олигонуклеотидные праймеры пригодны для выполнения полимеразной цепной реакции с обратной транскрипцией (RT-PCR).
6. Способ классификации образца ткани рака молочной железы, который включает:
(а) измерение экспрессии генов в образце ткани в следующих дескрпиторных группах:
(1) ERBB2, STARD3, GRB7, THRAP4, PPARBP;
(2) ESR1, GATA3, XBP1, TFF3, ACADSB;
(3) KRT5, KRT17, TRIM29, GABRP;
(4) KRT18, KRT8, PPP2CA, KRT8L2;
(5) PLAU, COL5A2, FAP, THY1;
(6) STAT1, UBE2L6, TAP1, LAP3 и
(7) SEACAM5, SEACAM6, SEACAM7;
(b) присвоение положительного или отрицательного статуса каждой из дескрипторных групп с учетом сверхэкспрессии большинства генов в группе; и
(с) использование комбинации положительных и/или отрицательных статусов дескрипторных групп для образования характерных генов для классификации образца ткани рака молочной железы.
7. Способ по п.6, в котором стадия а) включает реакцию гибридизации или амплификации нуклеотидов.
8. Способ по п.7, в котором реакция гибридизации нуклеотидов выполнена на твердом носителе.
9. Способ по п.8, в котором реакция гибридизации нуклеотидов выполнена на олигонуклеотидной матрице.
10. Способ по п.7, в котором реакция амплификации нуклеотидов является полимеразной цепной реакцией с обратной транскрипцией (RT-PCR).
11. Способ оценки инвазивности рака молочной железы, который включает:
а) получение образца ткани рака молочной железы у индивида, страдающего раком молочной железы;
b) классификацию указанного образца ткани способом по п.6;
с) оценку инвазивности рака молочной железы по результатам, полученным на стадии b).
12. Способ оценки клинического прогноза для индивида, страдающего раком молочной железы, который включает:
а) получение образца ткани рака молочной железы у индивида;
b) классификацию указанного образца ткани способом по п.6;
с) оценку клинического прогноза для индивида, страдающего раком молочной железы, по результатам, полученным на стадии b).
13. Способ определения курса лечения для индивида, страдающего раком молочной железы, который включает:
а) получение образца ткани рака молочной железы у индивида;
b) классификацию указанного образца ткани способом по п.6;
с) определение курса лечения для индивида, страдающего раком молочной железы, по результатам, полученным на стадии b).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87564806P | 2006-12-19 | 2006-12-19 | |
| US60/875,648 | 2006-12-19 | ||
| PCT/US2007/026014 WO2008079269A2 (en) | 2006-12-19 | 2007-12-19 | Novel methods for functional analysis of high-throughput experimental data and gene groups identified therfrom |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2009127709A true RU2009127709A (ru) | 2011-01-27 |
| RU2473555C2 RU2473555C2 (ru) | 2013-01-27 |
Family
ID=39563081
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009127709/10A RU2473555C2 (ru) | 2006-12-19 | 2007-12-19 | Новые способы функционального анализа большого количества экспериментальных данных и групп генов, идентифицированных из указанных данных |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US9353415B2 (ru) |
| EP (1) | EP2094719A4 (ru) |
| RU (1) | RU2473555C2 (ru) |
| WO (1) | WO2008079269A2 (ru) |
Families Citing this family (136)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8768629B2 (en) | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
| CA2651995C (en) | 2006-05-18 | 2017-04-25 | Molecular Profiling Institute, Inc. | System and method for determining individualized medical intervention for a disease state |
| JP6115801B2 (ja) * | 2007-03-27 | 2017-04-19 | イミュノヴィア・アーベー | 腺癌の検出のための蛋白質シグネチャー／マーカー |
| WO2008132167A2 (en) * | 2007-04-26 | 2008-11-06 | Dublin City University | Diagnostic, prognostic and/or predictive indicators of breast cancer |
| WO2009020028A1 (ja) * | 2007-08-03 | 2009-02-12 | Konica Minolta Holdings, Inc. | 乳癌細胞におけるｇタンパク質共役型受容体キナーゼ４遺伝子発現量の定量および抑制 |
| WO2009055823A2 (en) * | 2007-10-26 | 2009-04-30 | Progen Pharmaceuticals Limited | Method to predict responsiveness of breast cancer to polyaminetype chemotherapy |
| BRPI0820707A2 (pt) * | 2007-11-07 | 2015-06-16 | Genentech Inc | Métodos e composição para avaliar a responsividade do linfoma de células b para o tratamento com anticorpos anti-cd40 |
| DE102008031699A1 (de) * | 2008-07-04 | 2010-01-14 | Protagen Ag | Markersequenzen für Prostataentzündungserkrankungen, Prostatakarzinom und deren Verwendung |
| EP2151505A1 (en) * | 2008-08-05 | 2010-02-10 | Institut Gustave Roussy | Method for determining a predisposition to basal cell carcinoma and for screening treatments thereof |
| US8285719B1 (en) | 2008-08-08 | 2012-10-09 | The Research Foundation Of State University Of New York | System and method for probabilistic relational clustering |
| CN102224256A (zh) * | 2008-08-27 | 2011-10-19 | H.隆德贝克有限公司 | 用于测量生物标记概况的系统和方法 |
| US20120115735A1 (en) * | 2008-09-03 | 2012-05-10 | The Johns Hopkins University | Pathways Underlying Pancreatic Tumorigenesis and an Hereditary Pancreatic Cancer Gene |
| US8367415B2 (en) * | 2008-09-05 | 2013-02-05 | University Of South Carolina | Specific gene polymorphisms in breast cancer diagnosis, prevention and treatment |
| WO2010030167A2 (en) * | 2008-09-12 | 2010-03-18 | Cancer Research Initiative Foundation | Method of detection and diagnosis of oral and nasopharyngeal cancers |
| WO2010045318A2 (en) * | 2008-10-14 | 2010-04-22 | Caris Mpi, Inc. | Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type |
| US8735082B2 (en) * | 2008-11-10 | 2014-05-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Gene signature for predicting prognosis of patients with solid tumors |
| WO2011109440A1 (en) | 2010-03-01 | 2011-09-09 | Caris Life Sciences Luxembourg Holdings | Biomarkers for theranostics |
| CN107254538A (zh) | 2008-11-12 | 2017-10-17 | 卡里斯生命科学瑞士控股有限责任公司 | 使用外来体来确定表现型的方法和系统 |
| CA2743464A1 (en) * | 2008-11-14 | 2010-05-20 | The Brigham And Women's Hospital, Inc. | Therapeutic and diagnostic methods relating to cancer stem cells |
| US11542328B2 (en) | 2008-11-14 | 2023-01-03 | The Brigham And Women's Hospital, Inc. | Therapeutic and diagnostic methods relating to cancer stem cells |
| WO2010066150A1 (zh) * | 2008-12-08 | 2010-06-17 | 清华大学 | 基于基因网络确定药物作用的方法 |
| WO2010088386A1 (en) | 2009-01-28 | 2010-08-05 | University Of Notre Dame Du Lac | Accelerated progression relapse test |
| US8972899B2 (en) | 2009-02-10 | 2015-03-03 | Ayasdi, Inc. | Systems and methods for visualization of data analysis |
| ES2605228T3 (es) | 2009-04-18 | 2017-03-13 | Genentech, Inc. | Métodos para evaluar la capacidad de respuesta de un linfoma de células B al tratamiento con anticuerpos anti-CD40 |
| AU2010264763B2 (en) * | 2009-06-26 | 2015-07-23 | Noviogendix Research B.V. | Molecular markers in kidney cancer |
| GB0911569D0 (en) | 2009-07-03 | 2009-08-12 | Ulive Entpr Ltd | Method for the detection of organ or tissue injury |
| US8980269B2 (en) | 2009-07-14 | 2015-03-17 | Temple University Of The Commonwealth System Of Higher Education | G-protein coupled receptor-associated sorting protein 1 as a cancer biomarker |
| US8420333B2 (en) * | 2009-07-14 | 2013-04-16 | Temple University Of The Commonwealth System Of Higher Education | G-protein coupled receptor-associated sorting protein 1 as a cancer biomarker |
| AU2010273543B2 (en) | 2009-07-14 | 2017-06-15 | Temple University Of The Commonwealth System Of Higher Education | Serum markers associated with early and other stages of breast cancer |
| WO2011073901A1 (en) * | 2009-12-14 | 2011-06-23 | Koninklijke Philips Electronics N.V. | Novel tumor markers |
| CN102686745B (zh) * | 2009-12-24 | 2014-01-29 | 国立大学法人爱媛大学 | 颈部淋巴结转移分析方法及头颈癌的肿瘤标记物 |
| US9624547B2 (en) | 2010-02-10 | 2017-04-18 | The Regents Of The University Of California | Salivary transcriptomic and proteomic biomarkers for breast cancer detection |
| ES2525382T3 (es) * | 2010-03-31 | 2014-12-23 | Sividon Diagnostics Gmbh | Método para la predicción de recurrencia del cáncer de mama bajo tratamiento endocrino |
| US9469876B2 (en) | 2010-04-06 | 2016-10-18 | Caris Life Sciences Switzerland Holdings Gmbh | Circulating biomarkers for metastatic prostate cancer |
| US20130251710A1 (en) * | 2010-04-23 | 2013-09-26 | Nsabp Foundation, Inc. | Methods to Expand the Eligible Patient Population for HER2-Directed Targeted Therapies |
| CN102269766B (zh) * | 2010-06-01 | 2015-08-26 | 北京大学 | 人类基因fam96a及其蛋白质的应用 |
| CA2802631C (en) | 2010-06-14 | 2019-12-17 | Lykera Biomed Sa | S100a4 antibodies and therapeutic uses thereof |
| PT2829881T (pt) * | 2010-07-14 | 2017-11-29 | Commw Scient Ind Res Org | Diagnóstico para cancro colo-rectal |
| GB201018312D0 (en) * | 2010-10-29 | 2010-12-15 | Vib Vzw | Metagene expression signature for prognosis of breast cancer patients |
| CN102183655B (zh) * | 2011-01-24 | 2014-06-11 | 中国人民解放军军事医学科学院生物医学分析中心 | 用于乳腺癌内分泌治疗预后判断的新的分子标志物cuedc2蛋白质 |
| RU2013140708A (ru) * | 2011-02-04 | 2015-03-10 | Конинклейке Филипс Н.В. | Способ для оценки потока информации в биологических сетях |
| GB201103726D0 (en) | 2011-03-04 | 2011-04-20 | Immunovia Ab | Method, array and use thereof |
| WO2012122106A2 (en) * | 2011-03-04 | 2012-09-13 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Compositions and methods apc, creb, and bad pathways to assess and affect cancer |
| WO2012130165A1 (zh) * | 2011-03-31 | 2012-10-04 | 中国科学院上海生命科学研究院 | 一种诊断肝癌的标记物及其应用 |
| EP2527459A1 (en) * | 2011-05-02 | 2012-11-28 | Rheinische Friedrich-Wilhelms-Universität Bonn | Blood-based gene detection of non-small cell lung cancer |
| WO2012154567A2 (en) * | 2011-05-06 | 2012-11-15 | Albert Einstein College Of Medicine Of Yeshiva University | Human invasion signature for prognosis of metastatic risk |
| EP2723924A4 (en) * | 2011-06-22 | 2015-03-25 | Oncocyte Corp | METHOD AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF CANCER |
| ES2398328B1 (es) | 2011-08-09 | 2014-02-05 | Oncomatrix, S.L. | Métodos y productos para el diagnóstico in vitro, pronóstico in vitro y desarrollo de fármacos contra carcinomas invasivos. |
| JP2014525584A (ja) * | 2011-08-31 | 2014-09-29 | オンコサイト コーポレーション | 癌の治療および診断のための方法および組成物 |
| US20140214336A1 (en) * | 2011-09-09 | 2014-07-31 | Philip Morris Products S.A. | Systems and methods for network-based biological activity assessment |
| US9409978B2 (en) | 2011-09-09 | 2016-08-09 | University Of Massachusetts | Modulation of midbody derivatives |
| WO2013043132A1 (en) | 2011-09-23 | 2013-03-28 | Agency For Science, Technology And Research | Patient stratification and determining clinical outcome for cancer patients |
| CN102352368B (zh) * | 2011-09-29 | 2013-12-04 | 苏州大学 | Ing4与osm双基因共表达载体及其应用 |
| SE536352C2 (sv) | 2011-10-24 | 2013-09-03 | Chundsell Medicals Ab | Markörgener för klassificiering av prostatacancer |
| JP6259764B2 (ja) | 2011-10-24 | 2018-01-10 | シグナルケム・ライフサイエンシーズ・コーポレイションＳｉｇｎａｌｃｈｅｍ Ｌｉｆｅｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ | 炭酸脱水酵素関連マーカーおよびその使用 |
| WO2013070521A1 (en) * | 2011-11-08 | 2013-05-16 | Genomic Health, Inc. | Method of predicting breast cancer prognosis |
| WO2013144202A1 (en) * | 2012-03-29 | 2013-10-03 | Roche Diagnostics Gmbh | Biomarkers for discriminating healthy and/or non-malignant neoplastic colorectal cells from colorectal cancer cells |
| US20130268290A1 (en) * | 2012-04-02 | 2013-10-10 | David Jackson | Systems and methods for disease knowledge modeling |
| EP2834371B1 (en) * | 2012-04-05 | 2019-01-09 | The Regents of The University of California | Gene expression panel for breast cancer prognosis |
| US20150285807A1 (en) * | 2012-06-11 | 2015-10-08 | The Brigham And Women's Hospital, Inc. | System and method for detecting cancer |
| EP2864920B1 (en) | 2012-06-21 | 2023-05-10 | Philip Morris Products S.A. | Systems and methods for generating biomarker signatures with integrated bias correction and class prediction |
| CN104584022B (zh) | 2012-06-21 | 2018-11-16 | 菲利普莫里斯生产公司 | 一种生成生物标记签名的系统及方法 |
| CN102994627B (zh) * | 2012-06-21 | 2015-04-15 | 宁波海尔施基因科技有限公司 | 一种肿瘤用药个体化指导的检测方法 |
| BR112014032728A2 (pt) | 2012-06-27 | 2017-11-28 | Berg Llc | uso de marcadores no diagnóstico e tratamento de câncer de próstata |
| KR20140009854A (ko) * | 2012-07-13 | 2014-01-23 | 삼성전자주식회사 | 치료제 선정을 위한 유전 정보의 분석 방법 및 장치 |
| US9336302B1 (en) | 2012-07-20 | 2016-05-10 | Zuci Realty Llc | Insight and algorithmic clustering for automated synthesis |
| CA2884637A1 (en) * | 2012-09-12 | 2014-03-20 | Berg Llc | Use of markers in the identification of cardiotoxic agents |
| WO2014089055A1 (en) * | 2012-12-03 | 2014-06-12 | Aveo Pharmaceuticals, Inc. | Tivozanib response prediction |
| CN104871002A (zh) * | 2012-12-20 | 2015-08-26 | 国立大学法人北海道大学 | 用于检测前列腺基底细胞的方法 |
| CN103074436B (zh) * | 2013-01-25 | 2014-07-16 | 宁波海尔施基因科技有限公司 | 一种指导5-氟尿嘧啶用药的多重基因检测试剂盒及其检测方法 |
| KR20150113113A (ko) | 2013-01-29 | 2015-10-07 | 몰레큘러 헬스 게엠베하 | 임상적 판단 지원을 위한 시스템 및 방법 |
| ES2654469T3 (es) | 2013-02-01 | 2018-02-13 | Sividon Diagnostics Gmbh | Procedimiento de predicción del beneficio de la inclusión de taxano en un régimen de quimioterapia en pacientes con cáncer de mama |
| ES2485615B8 (es) * | 2013-02-12 | 2015-06-05 | Oncomatryx Biopharma, S.L. | Métodos y productos para pronosticar la evolución clínica o predecir el riesgo de recidiva de una lesión papilar de mama |
| WO2014173912A1 (en) * | 2013-04-23 | 2014-10-30 | Philip Morris Products S.A. | Systems and methods for using mechanistic network models in systems toxicology |
| GB201317609D0 (en) | 2013-10-04 | 2013-11-20 | Cancer Rec Tech Ltd | Inhibitor compounds |
| US20150220680A1 (en) * | 2014-01-31 | 2015-08-06 | International Business Machines Corporation | Inferring biological pathways from unstructured text analysis |
| KR101665565B1 (ko) * | 2014-07-28 | 2016-10-14 | 전남대학교산학협력단 | 상피세포 성장인자 수용체 차단 치료제에 대해 저항성을 갖는 암을 치료할 수 있는 항암제의 스크리닝 방법 |
| BR112017005730B1 (pt) * | 2014-09-26 | 2023-12-12 | Somalogic Operating Co., Inc | Método para triagem de um indivíduo quanto ao risco de um evento cardiovascular ou para predizer a probabilidade que um indivíduo tenha tal evento |
| WO2016094425A1 (en) | 2014-12-08 | 2016-06-16 | Berg Llc | Use of markers including filamin a in the diagnosis and treatment of prostate cancer |
| GB201505658D0 (en) | 2015-04-01 | 2015-05-13 | Cancer Rec Tech Ltd | Inhibitor compounds |
| CN104805197A (zh) * | 2015-04-09 | 2015-07-29 | 嘉兴市第二医院 | 分子标志物用于乳腺癌诊断和预后评估的方法 |
| CN113881694A (zh) * | 2015-06-24 | 2022-01-04 | 学校法人庆应义塾 | 抗磷脂酰肌醇蛋白聚糖-1-免疫抗原受体 |
| CN105092844A (zh) * | 2015-07-10 | 2015-11-25 | 深圳市贝沃德克生物技术研究院有限公司 | 胰腺癌蛋白生物标记物的检测试剂盒及检测系统 |
| CN105092845A (zh) * | 2015-07-10 | 2015-11-25 | 深圳市贝沃德克生物技术研究院有限公司 | 胰腺癌蛋白生物标记物、用途及其检测芯片和检测装置 |
| JP6760666B2 (ja) * | 2015-07-22 | 2020-09-23 | ミノミック インターナショナル リミティド | 前立腺疾患のためのバイオマーカーの組み合わせ |
| US10443103B2 (en) * | 2015-09-16 | 2019-10-15 | Innomedicine, LLC | Chemotherapy regimen selection |
| US20170154163A1 (en) * | 2015-12-01 | 2017-06-01 | Ramot At Tel-Aviv University Ltd. | Clinically relevant synthetic lethality based method and system for cancer prognosis and therapy |
| WO2017127550A1 (en) * | 2016-01-19 | 2017-07-27 | Wayne State University | Prostate cancer aggressiveness gene signatures for subjects of african or european descent |
| CN105986031B (zh) * | 2016-02-04 | 2019-12-20 | 北京肿瘤医院 | 肿瘤易感62基因及其应用 |
| US11613784B2 (en) * | 2016-03-25 | 2023-03-28 | The Trustees Of Columbia University In The City Of New York | Next-generation biomarkers to detect sun damage and predict skin cancer risk |
| SE540173C2 (en) * | 2016-04-20 | 2018-04-24 | Hiloprobe Ab | Marker genes for colorectal cancer classification, method for judging lymph node metastasis for prognosis of colorectal cancer and kit therefor |
| CN107574243B (zh) * | 2016-06-30 | 2021-06-29 | 博奥生物集团有限公司 | 分子标志物、内参基因及其应用、检测试剂盒以及检测模型的构建方法 |
| GB201617103D0 (en) | 2016-10-07 | 2016-11-23 | Cancer Research Technology Limited | Compound |
| US20200051661A1 (en) * | 2016-10-18 | 2020-02-13 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Pharmacogenomics of Intergenic Single-Nucleotide Polymorphisms and in Silico Modeling for Precision Therapy |
| WO2018074865A2 (ko) * | 2016-10-21 | 2018-04-26 | 서울대학교병원 | 유방암 예후 예측용 조성물 및 방법 |
| JP6280997B1 (ja) * | 2016-10-31 | 2018-02-14 | 株式会社Preferred Networks | 疾患の罹患判定装置、疾患の罹患判定方法、疾患の特徴抽出装置及び疾患の特徴抽出方法 |
| US11205103B2 (en) | 2016-12-09 | 2021-12-21 | The Research Foundation for the State University | Semisupervised autoencoder for sentiment analysis |
| US20180166170A1 (en) * | 2016-12-12 | 2018-06-14 | Konstantinos Theofilatos | Generalized computational framework and system for integrative prediction of biomarkers |
| CN106636388A (zh) * | 2016-12-15 | 2017-05-10 | 湖南中能荆卫生物科技有限公司 | 用于亨廷顿病诊断的基因及其应用以及由其编码的蛋白和蛋白的应用 |
| CN106755445B (zh) * | 2016-12-30 | 2020-09-15 | 广州市达瑞生物技术股份有限公司 | 一种检测结直肠癌kras/nras/braf/pik3ca基因的方法及试剂盒 |
| CN106811528B (zh) * | 2017-02-24 | 2019-10-18 | 北京致成生物医学科技有限公司 | 一种乳腺癌治病基因新突变及其应用 |
| WO2018194423A1 (ko) * | 2017-04-21 | 2018-10-25 | 아이씨엠 주식회사 | Nkx3.2 및 이의 단편을 유효성분으로 포함하는 망막질환 치료용 약학적 조성물 |
| CN109321654A (zh) * | 2017-07-27 | 2019-02-12 | 张巍 | 用于多基因联合检测妇科肿瘤的引物组、试剂盒、文库及应用 |
| EP3679160A4 (en) | 2017-09-08 | 2021-05-19 | Myriad Genetics, Inc. | Method of using biomarkers and clinical variables for predicting chemotherapy benefit |
| CN107574249B (zh) * | 2017-10-23 | 2020-12-25 | 江苏省肿瘤防治研究所（江苏省肿瘤医院） | 一种预测中国人群乳腺癌复发的基因表达谱检测试剂盒 |
| US10934594B2 (en) * | 2017-11-30 | 2021-03-02 | Mayo Foundation For Medical Education And Research | Detecting breast cancer |
| CN109870576B (zh) * | 2017-12-05 | 2021-08-10 | 中国科学院大连化学物理研究所 | Usp10蛋白的定量检测在原发性肝癌预后判断试剂盒中的应用 |
| EP3502279A1 (en) | 2017-12-20 | 2019-06-26 | Koninklijke Philips N.V. | Assessment of mapk-ap 1 cellular signaling pathway activity using mathematical modelling of target gene expression |
| CN110272986B (zh) * | 2018-03-16 | 2023-01-03 | 上海交通大学医学院附属第九人民医院 | 针对xy性发育异常疾病的靶向检测 |
| GB201806052D0 (en) | 2018-04-12 | 2018-05-30 | Univ Liverpool | Detection of bacterial infections |
| EP3810795A4 (en) * | 2018-06-21 | 2022-07-06 | China Medical University | BIOMARKERS FOR UROTHELIAL CANCER AND APPLICATIONS THEREOF |
| US20210317535A1 (en) * | 2018-08-29 | 2021-10-14 | The Regents Of The University Of Michigan | Methods of determining treatment consisting of radiation therapy and/or alkylating chemotherapy in patients suffering from cancer |
| CN108866199B (zh) * | 2018-09-10 | 2022-02-01 | 山东大学齐鲁医院 | 一种用于乳腺癌诊断mRNA标志物及其检测试剂盒与应用 |
| CN109097466B (zh) * | 2018-09-21 | 2022-07-15 | 王赞鑫 | 与主动脉夹层疾病相关的snp位点及其应用 |
| JP7243005B2 (ja) * | 2018-10-19 | 2023-03-22 | アイシーエム・カンパニー、リミテッド | Ｎｋｘ３．２及びその断片を有効成分として含む網膜疾患治療用の医薬組成物 |
| GB201817651D0 (en) * | 2018-10-29 | 2018-12-12 | Univ College Dublin Nat Univ Ireland Dublin | Method for predicting effectiveness of treatments for cancer patients |
| CN111257482B (zh) * | 2018-11-30 | 2021-11-09 | 中国科学院大连化学物理研究所 | 一种细胞内mtdh结合代谢物的鉴定方法 |
| CN109355392A (zh) * | 2018-12-07 | 2019-02-19 | 上海产业技术研究院 | 乳腺癌高风险基因的诊断试剂盒及其应用 |
| CN111755066B (zh) * | 2019-03-27 | 2022-10-18 | 欧蒙医学诊断（中国）有限公司 | 一种拷贝数变异的检测方法和实施该方法的设备 |
| CN110133274B (zh) * | 2019-03-29 | 2022-03-25 | 南方医科大学南方医院 | Igfbpl1作为标志物在制备心血管疾病诊断试剂中的应用 |
| CN110261609A (zh) * | 2019-06-14 | 2019-09-20 | 上海四核生物科技有限公司 | Zbtb5蛋白作为胃癌血清生物标志物的应用及其试剂盒 |
| CN112301125A (zh) * | 2019-07-30 | 2021-02-02 | 立森印迹诊断技术（无锡）有限公司 | 一种肿瘤标志物及其应用 |
| WO2021030358A1 (en) | 2019-08-12 | 2021-02-18 | Regeneron Pharmaceuticals, Inc. | Macrophage stimulating 1 receptor (mst1r) variants and uses thereof |
| CN110747276B (zh) * | 2019-11-22 | 2020-06-30 | 山东大学齐鲁医院 | Bace2作为胶质瘤预后/诊断/治疗标志物的应用 |
| EP4073807A4 (en) | 2019-12-12 | 2024-05-01 | Tempus AI, Inc. | REAL-WORLD EVIDENCE OF DIAGNOSTIC TESTS AND TREATMENT REGIMENS IN US PATIENTS WITH BREAST CANCER |
| CN111440872A (zh) * | 2020-05-07 | 2020-07-24 | 杭州和壹基因科技有限公司 | 一种用于胃癌相关基因甲基化检测的试剂盒及其应用 |
| GB202010970D0 (en) | 2020-07-16 | 2020-09-02 | Immunovia Ab | Methods, arrays and uses thereof |
| WO2022090050A1 (en) * | 2020-10-26 | 2022-05-05 | Institut National De La Sante Et De La Recherche Medicale | Combination of biomarkers of preterm delivery |
| CN112634117B (zh) * | 2020-12-22 | 2023-05-05 | 中山大学 | 基于生成对抗网络的端到端jpeg域图像隐写方法 |
| CN113444793B (zh) * | 2021-05-31 | 2022-09-23 | 复旦大学附属中山医院 | 检测肺腺癌抗氧化应激通路相关基因突变的试剂盒 |
| CN113970638B (zh) * | 2021-10-24 | 2023-02-03 | 清华大学 | 确定胃癌极早期发生风险及评估胃癌前病变进展风险的分子标志及其在诊断试剂盒中的应用 |
| CN114783529A (zh) * | 2022-01-14 | 2022-07-22 | 中国人民解放军空军军医大学 | 木犀草素-孤独症相关作用基因靶点及其筛选方法 |
| CN114438232B (zh) * | 2022-03-11 | 2023-06-23 | 浙江省农业科学院 | SNPs分子标记g.43917 A＞G及其在湖羊分子标记辅助育种中的应用 |
| KR102884384B1 (ko) * | 2022-12-01 | 2025-11-11 | 서울대학교병원 | 대장암 진단용 바이오마커 조성물 및 이의 용도 |
| CN116359501A (zh) * | 2023-02-14 | 2023-06-30 | 南方医科大学 | 脂筏特征蛋白作为生物标志物在诊断乳腺癌中的应用 |
| CN119326891B (zh) * | 2024-10-31 | 2025-07-01 | 中国人民解放军空军军医大学 | Ei24激动剂以及在制备抑制食管鳞癌增殖的制剂的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6054270A (en) * | 1988-05-03 | 2000-04-25 | Oxford Gene Technology Limited | Analying polynucleotide sequences |
| US5474796A (en) * | 1991-09-04 | 1995-12-12 | Protogene Laboratories, Inc. | Method and apparatus for conducting an array of chemical reactions on a support surface |
| SG143055A1 (en) * | 2000-06-19 | 2008-06-27 | Correlogic Systems Inc | Heuristic method of classification |
| US8000949B2 (en) | 2001-06-18 | 2011-08-16 | Genego, Inc. | Methods for identification of novel protein drug targets and biomarkers utilizing functional networks |
| JP2005500832A (ja) * | 2001-06-18 | 2005-01-13 | ロゼッタ・インファーマティクス・インコーポレーテッド | 乳癌患者の診断および予後 |
| US20070219768A1 (en) | 2006-03-17 | 2007-09-20 | Sean Ekins | System and method for prediction of drug metabolism, toxicity, mode of action, and side effects of novel small molecule compounds |
| KR20080004551A (ko) * | 2005-04-01 | 2008-01-09 | 엔씨씨 테크놀로지 벤쳐스 피티이 리미티드 | 유방암 분류에 관한 재료 및 방법 |
-
2007
- 2007-12-19 US US12/520,441 patent/US9353415B2/en active Active
- 2007-12-19 RU RU2009127709/10A patent/RU2473555C2/ru not_active IP Right Cessation
- 2007-12-19 WO PCT/US2007/026014 patent/WO2008079269A2/en not_active Ceased
- 2007-12-19 EP EP20070863157 patent/EP2094719A4/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20100216660A1 (en) | 2010-08-26 |
| WO2008079269A2 (en) | 2008-07-03 |
| US9353415B2 (en) | 2016-05-31 |
| EP2094719A2 (en) | 2009-09-02 |
| RU2473555C2 (ru) | 2013-01-27 |
| WO2008079269A3 (en) | 2008-12-04 |
| EP2094719A4 (en) | 2010-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2009127709A (ru) | Новые способы функционального анализа большого количества экспериментальных данных и групп генов, идентифицированных из указанных данных | |
| JP5890686B2 (ja) | 敗血症の検出方法 | |
| JP2022188053A (ja) | 胃がん診断用のマイクロｒｎａバイオマーカー | |
| US8614058B2 (en) | Molecular prognostic signature for predicting breast cancer metastasis, and uses thereof | |
| US20090253583A1 (en) | Hematological Cancer Profiling System | |
| US20190241967A1 (en) | Methods to predict clinical outcome of cancer | |
| US20170159126A1 (en) | Gene for predicting the prognosis for early-stage breast cancer, and a method for predicting the prognosis for early-stage breast cancer by using the same | |
| JP5836397B2 (ja) | 結腸直腸がんの再発予測のためのバイオマーカー | |
| WO2016036994A1 (en) | Method of analysis allowing avoidance of surgery | |
| Crassini et al. | Molecular pathogenesis of chronic lymphocytic leukaemia | |
| CN105431738B (zh) | 胃癌的预后预测模型的建立方法 | |
| US20220259674A1 (en) | Compositions and methods for treating breast cancer | |
| US20100298160A1 (en) | Method and tools for prognosis of cancer in er-patients | |
| WO2012156515A1 (en) | Molecular analysis of acute myeloid leukemia | |
| US20220106627A1 (en) | Methods of diagnosing tuberculosis and differentiating between active and latent tuberculosis | |
| US20110306507A1 (en) | Method and tools for prognosis of cancer in her2+partients | |
| Yang et al. | Development of a focused microarray to assess human embryonic stem cell differentiation | |
| US20140323343A1 (en) | Biomarkers for assessing idiopathic pulmonary fibrosis | |
| KR101725985B1 (ko) | 초기유방암의 예후 예측용 유전자 및 이를 이용한 초기유방암의 예후예측 방법 | |
| EP2633068A1 (en) | Metagene expression signature for prognosis of breast cancer patients | |
| WO2014093504A1 (en) | Microrna biomarkers for graft versus host disease | |
| Wang et al. | Unique biological properties and application potentials of CD34+ CD38− stem cells from various sources | |
| KR102276224B1 (ko) | 비결핵 항산균에 의한 감염 또는 감염 질환의 진단용 조성물 | |
| JP2006223303A (ja) | 微量胃癌細胞の検出法 | |
| CN118048451A (zh) | 用于肝癌筛查的标志物、探针组合物及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC43 | Official registration of the transfer of the exclusive right without contract for inventions |
Effective date: 20161214 |
|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20181220 |